program overview

SIIA members consistently cite Cell & Gene Therapy (CGT) as one of the most important issues affecting the self-insurance industry, with this importance only expected to increase in the years ahead.

Responding to this feedback, SIIA is pleased to announce its inaugural Cell & Gene Therapy Stakeholder Forum. Join leading experts in the field as well as thought leaders from the self-insurance industry who will discuss the ongoing and mounting risk of paying for these potentially life-saving, yet high cost therapies.

You will leave with detailed knowledge of the CGT pipeline, manufacturer perspective on pricing, value-based pricing consideration, potential financial mitigation/risk strategies, plan document guidance and more.

Attendees will also have multiple opportunities to directly engage with each other, which promises to maximize the knowledge-sharing experience and to help facilitate business partnership opportunities.